CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 893-899

  Kogan, Michael ^a   Fischer Smith, Tracy ^a   Kaminsky, Rafal ^a   Lehmicke, Gabrielle ^a   Rappaport, Jay ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; cFMS; CSF 1; CSF 1R; Individualized medicine; Leukemia; M CSF; Tyrosine kinase

Indexed keywords

8 INDAN 5 YL 2 [4 (1 METHYLPIPERIDIN 4 YL)PHENYLAMINO] 5 OXO 5,8 DIHYDROPYRIDOL[2,3 D]PYRIMIDINE 6 CARBOXYLIC ACID METHOXYAMIDE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROTEIN-TYROSINE KINASES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84858786146     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Haine V, Fischer-Smith T and Rappaport J: Macrophage Colony-Stimulating Factor in Pathogenesis of HIV Infection: Potential Target for Therapeutic Intervention. J Neuroimmune Pharmacol 1: 1-19, 2006.
2. Pixley FJ and Stanley ER: CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 14(11): 628-638, 2004. (Pubitemid 39440612)
3. McDonough SK, Larsen S, Brodey RS, Stock ND and Hardy WD Jr.: A transmissible feline fibrosarcoma of viral origin. Cancer Res 31(7): 953-956, 1971.
4. Gisselbrecht S, Fichelson S, Sola B, Bordereaux D, Hampe A, Andre C, Galibert F and Tambourin P: Frequent c-fms activation by proviral insertion in mouse myeloblastic leukaemias. Nature 329(6136): 259-261, 1987. (Pubitemid 17128971)
5. Woolford J, McAuliffe A and Rohrschneider LR: Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell 55(6): 965-977, 1988. (Pubitemid 19020050)
6. Roussel MF, Dull TJ, Rettenmier CW, Ralph P, Ullrich A and Sherr CJ: Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature 325(6104): 549-552, 1987. (Pubitemid 17056741)
7. Browning PJ, Bunn HF, Cline A, Shuman M and Nienhuis AW: "Replacement" of COOH-terminal truncation of v-fms with c-fms sequences markedly reduces transformation potential. Proc Natl Acad Sci USA 83(20): 7800-7804, 1986. (Pubitemid 17183932)
8. Roussel MF, Downing JR, Rettenmier CW and Sherr CJ: A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell 55(6): 979-988, 1988. (Pubitemid 19020051)
9. Wheeler EF, Askew D, May S, Ihle JN and Sherr CJ: The v-fms oncogene induces factor-independent growth and transformation of the interleukin-3- dependent myeloid cell line FDC-P1. Mol Cell Biol 7(5): 1673-1680, 1987. (Pubitemid 17059160)
10. Wheeler EF, Rettenmier CW, Look AT and Sherr CJ: The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line. Nature 324(6095): 377-380, 1986. (Pubitemid 17180115)
11. Parwaresch MR, Kreipe H, Felgner J, Heidorn K, Jaquet K, Bodewadt-Radzun S and Radzun HJ: M-CSF and M-CSF-receptor gene expression in acute myelomonocytic leukemias. Leuk Res 14(1): 27-37, 1990. (Pubitemid 20061900)
12. Ridge SA, Worwood M, Oscier D, Jacobs A and Padua RA: FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 87(4): 1377-1380, 1990.
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9(1): 327-337, 2003. (Pubitemid 36109749)
14. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC and Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9): 3597-3605, 2003. (Pubitemid 36857948)
15. Mashkani B, Griffith R and Ashman LK: Colony stimulating factor-1 receptor as a target for small molecule inhibitors. Bioorg Med Chem 18(5): 1789-1797, 2010.
16. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM and Pryer NK: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20(8): 757-766, 2003. (Pubitemid 38019277)
17. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE and Hossfeld DK: A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3): 986-993, 2005. (Pubitemid 40170865)
18. Nishioka C, Ikezoe T, Yang J, Takeshita A, Taniguchi A, Komatsu N, Togitani K, Koeffler HP and Yokoyama A: Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene. Leuk Res 32(6): 865-872, 2008. (Pubitemid 351389543)
19. Siendones E, Barbarroja N, Torres LA, Buendia P, Velasco F, Dorado G, Torres A and Lopez-Pedrera C: Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors. Hematol Oncol 25(1): 30-37, 2007. (Pubitemid 46474312)
20. Nishioka C, Ikezoe T, Yang J and Yokoyama A: Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3). Leukemia 23(11): 2171-2173, 2009.
21. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS et al: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 167(4): 1428-1441, 1988.
22. Genois N, Robichaud GA and Tremblay MJ: Mono Mac 1: a new in vitro model system to study HIV-1 infection in human cells of the mononuclear phagocyte series. J Leukoc Biol 68(6): 854-864, 2000.
23. Auwerx J: The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia 47(1): 22-31, 1991.
24. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T and Tada K: Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 26(2): 171-176, 1980. (Pubitemid 10086416)
25. Sundstrom C and Nilsson K: Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17(5): 565-577, 1976.
26. Collins SJ: The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70(5): 1233-1244, 1987.
27. Huang H, Hutta DA, Rinker JM, Hu H, Parsons WH, Schubert C, DesJarlais RL, Crysler CS, Chaikin MA, Donatelli RR, Chen Y, Cheng D, Zhou Z, Yurkow E, Manthey CL and Player MR: Pyrido[23-d]pyrimidin-5-ones: a novel class of antiinflammatory macrophage colony-stimulating factor-1 receptor inhibitors. J Med Chem 52(4): 1081-1099, 2009.
28. Fujita N, Sato S and Tsuruo T: Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 278(49): 49254-49260, 2003.
29. Bhatt NY, Kelley TW, Khramtsov VV, Wang Y, Lam GK, Clanton TL and Marsh CB: Macrophage-colony-stimulating factor-induced activation of extracellular-regulated kinase involves phosphatidylinositol 3-kinase and reactive oxygen species in human monocytes. J Immunol 169(11): 6427-6434, 2002. (Pubitemid 36903492)
30. Kelley TW, Graham MM, Doseff AI, Pomerantz RW, Lau SM, Ostrowski MC, Franke TF and Marsh CB: Macrophage colony-stimulating factor promotes cell survival through Akt/protein kinase B. J Biol Chem 274(37): 26393-26398, 1999.
31. Roux PP and Blenis J: ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68(2): 320-344, 2004. (Pubitemid 38756868)